RCE — Recce Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$136.48m
- AU$132.62m
- AU$4.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 255.49 | ||
| Price to Tang. Book | 255.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1317% | ||
| Return on Equity | -1277.62% | ||
| Operating Margin | -159.48% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.69 | 1.15 | 1.96 | 3.18 | 4.43 | 5.77 | 6.69 | 27.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company’s anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are 100% water soluble at all pH levels in their liquid form.
Directors
- John Prendergast CHM
- James Graham CEO
- Michele Dilizia CSO
- Alistair McKeough SEC
- Justin Ward DRC
- Alan Dunton NID (67)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 11th, 2007
- Public Since
- January 15th, 2016
- No. of Shareholders
- 4,494
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 203,701,863
- Address
- Level 23, SYDNEY, 2000
- Web
- https://www.recce.com.au/
- Phone
- +61 292562505
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for RCE
Similar to RCE
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Recce Pharmaceuticals share price?
As of Today at 19:18 UTC, shares in Recce Pharmaceuticals are trading at AU$0.67. This share price information is delayed by 15 minutes.
How has the Recce Pharmaceuticals share price performed this year?
Shares in Recce Pharmaceuticals last closed at AU$0.67 and the price had moved by +5.51% over the past 365 days. In terms of relative price strength the Recce Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -0.54% over the past year.
What are the analyst and broker recommendations for Recce Pharmaceuticals?
There is no consensus recommendation for this security.
What is the Recce Pharmaceuticals dividend yield?
Recce Pharmaceuticals does not currently pay a dividend.
Does Recce Pharmaceuticals pay a dividend?
Recce Pharmaceuticals does not currently pay a dividend.
When does Recce Pharmaceuticals next pay dividends?
Recce Pharmaceuticals does not currently pay a dividend.
How do I buy Recce Pharmaceuticals shares?
To buy shares in Recce Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Recce Pharmaceuticals?
As of the previous close price of AU$0.67, shares in Recce Pharmaceuticals had a market capitalisation of AU$136.48m.
Where are Recce Pharmaceuticals shares listed?
Here are the trading details for Recce Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RCE
What kind of share is Recce Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Recce Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Recce Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Recce Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Recce Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +30.56%.
As of the last closing price of AU$0.67, shares in Recce Pharmaceuticals were trading +29.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Recce Pharmaceuticals PE Ratio?
The Recce Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Recce Pharmaceuticals?
Recce Pharmaceuticals' management team is headed by:
- John Prendergast - CHM
- James Graham - CEO
- Michele Dilizia - CSO
- Alistair McKeough - SEC
- Justin Ward - DRC
- Alan Dunton - NID